Cutting the Brakes on Ras-Cytoplasmic GAPs as Targets of Inactivation in Cancer
The Ras pathway is frequently deregulated in cancer, actively contributing to tumor development and progression. Oncogenic activation of the Ras pathway is commonly due to point mutation of one of the three Ras genes, which occurs in almost one third of human cancers. In the absence of Ras mutation,...
Main Authors: | Arianna Bellazzo, Licio Collavin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/3066 |
Similar Items
-
RAS as Supporting Actor in Breast Cancer
by: Mirco Galiè
Published: (2019-11-01) -
The quest for targets executing MYC-dependent cell transformation
by: Markus eHartl
Published: (2016-06-01) -
Ras and Ras mutations in cancer
by: Rajasekharan Satish, et al.
Published: (2013-07-01) -
BRCA1 Partially Reverses the Transforming Activity of the ras Oncogene
by: Abhay Kumar, et al.
Published: (1999-11-01) -
A Histidine pH sensor regulates activation of the Ras-specific guanine nucleotide exchange factor RasGRP1
by: Yvonne Vercoulen, et al.
Published: (2017-09-01)